Dr. Martens plc
United Kingdom · GB00BL6NGV24 · reports in GBP · Europe
Four figures
From the annual report for the year to Mar 29, 2026. Each line says what it is based on.
- Revenue growth
- Revenue −2.9% in the year to Mar 29, 2026, on the year before.
- Return on equity
- It earned 6.6% on its shareholders' equity in the year to Mar 29, 2026.
- Equity and assets
- Equity is 41% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Mar 29, 2026, consolidated, in GBP.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Revenue | £1.0B | £877M | £788M | £765M |
| Earnings per share | £0.13 | £0.07 | £0.01 | £0.03 |
| Dividend per share | £0.06 | £0.03 | n/a | n/a |
| Cash from operations | £73M | £168M | £196M | £143M |
| Capital spending | £40M | £18M | £8M | £9M |
| Cash | £158M | £111M | £156M | £180M |
| Total assets | £993M | £952M | £890M | £877M |
| Equity | £404M | £368M | £366M | £362M |
What they do
In the company's own words, from the annual report.
The principal activity of the Company and its subsidiaries (together referred to as the ‘Group’) is the design, development, procurement, marketing, selling and distribution of footwear under the Dr. Martens brand.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.